Search

Your search keyword '"Schetelig, Johannes"' showing total 8 results
Start Over Author "Schetelig, Johannes" Journal blood advances
8 results on '"Schetelig, Johannes"'

1. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Author

Stilgenbauer, Stephan, Tausch, Eugen, Roberts, Andrew W., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Hillmen, Peter, Schneider, Christof, Schetelig, Johannes, Böttcher, Sebastian, Kater, Arnon P., Jiang, Yanwen, Boyer, Michelle, Popovic, Relja, Ghanim, Majd T., Moran, Michael, Sinai, Wendy J., Wang, Xifeng, Mukherjee, Nabanita, Chyla, Brenda, Wierda, William G., and Seymour, John F.

Published
2024
Full Text
View/download PDF

2. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

Author

Fein, Joshua A., Shouval, Roni, Krieger, Elizabeth, Spellman, Stephen R., Wang, Tao, Baldauf, Henning, Fleischhauer, Katharina, Kröger, Nicolaus, Horowitz, Mary, Maiers, Martin, Miller, Jeffrey S, Mohty, Mohamad, Nagler, Arnon, Weisdorf, Daniel, Malmberg, Karl-Johan, Toor, Amir A., Schetelig, Johannes, Romee, Rizwan, and Koreth, John

Published
2024
Full Text
View/download PDF

3. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

Author

Heidenreich, Falk, Falk, Bose, Baldauf, Henning, Massalski, Carolin, Schäfer, Gesine, Rücker-Braun, Elke, Altmann, Heidi, Sauter, Jürgen, Solloch, Ute V., Lange, Vinzenz, Stölzel, Friedrich, Röllig, Christoph, Middeke, Jan M., von Bonin, Malte, Thiede, Christian, Schäfer-Eckart, Kerstin, Müller-Tidow, Carsten, Krause, Stefan W., Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Serve, Hubert, Neubauer, Andreas, Bornhäuser, Martin, Schmidt, Alexander H., and Schetelig, Johannes

Published
2023
Full Text
View/download PDF

4. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Published
2022
Full Text
View/download PDF

5. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Published
2021
Full Text
View/download PDF

6. Large case-control study indicates no association of KIRgenotype and risk of developing acute myeloid leukemia

Author

Heidenreich, Falk, Falk, Bose, Baldauf, Henning, Massalski, Carolin, Schäfer, Gesine, Rücker-Braun, Elke, Altmann, Heidi, Sauter, Jürgen, Solloch, Ute V., Lange, Vinzenz, Stölzel, Friedrich, Röllig, Christoph, Middeke, Jan M., von Bonin, Malte, Thiede, Christian, Schäfer-Eckart, Kerstin, Müller-Tidow, Carsten, Krause, Stefan W., Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Serve, Hubert, Neubauer, Andreas, Bornhäuser, Martin, Schmidt, Alexander H., and Schetelig, Johannes

Abstract

•This large case-control study reveals no differences in the KIRand KIR-ligand genotype frequencies among patients with and without AML.•Results suggest steady-state KIR-mediated NK cell immunity does not define risk of AML, and NK immunity is disarmed as leukemic clones grow.

Published
2023
Full Text
View/download PDF

7. Impact of PTPN11mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Abstract

The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11mutations were associated with concomitant mutations in NPM1(63%), DNMT3A(37%), and NRAS(21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P< .001) and higher white blood cell counts (P= .007) compared with PTPN11wild-type patients. In a multivariable analysis, PTPN11mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P< .001), relapse-free survival (HR: 1.52; P= .013), and a lower rate of complete remission (odds ratio: 0.46; P= .008). Importantly, the deleterious effect of PTPN11mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11mutations (HR: 2.28; P< .001) but not found with dominant PTPN11mutations (HR: 1.07; P= .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.

Published
2021
Full Text
View/download PDF

8. Differential impact of IDH1/2mutational subclasses on outcome in adult AML: Results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Kramer, Michael, Eckardt, Jan–Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, Bonin, Malte von, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Abstract

Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2genes are amongst the most frequent alterations in acute myeloid leukemia (AML) and can be found in ~20% of patients at diagnosis. Among4930 patients (median age 56 years, interquartile range 45-66) with newly diagnosed, intensively treated AML,wehave identified IDH1mutations (mIDH1) in 423 (8.6%) and IDH2mutations (mIDH2)in575 (11.7%) patients.Overall, there were no differences in response rates or survival for patients with mIDH1or mIDH2compared to patients without mutated IDH1/2. However, distinct clinical and co-mutational phenotypes of the most common subtypes of IDH1/2 mutations could be associated with differences in outcome.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results